Literature DB >> 24912781

Critical differences in toxicity mechanisms in induced pluripotent stem cell-derived hepatocytes, hepatic cell lines and primary hepatocytes.

Anna-Karin M Sjogren1, Maria Liljevald, Björn Glinghammar, Johanna Sagemark, Xue-Qing Li, Anna Jonebring, Ian Cotgreave, Gabriella Brolén, Tommy B Andersson.   

Abstract

Human-induced pluripotent stem cell-derived hepatocytes (hiPSC-Hep) hold great potential as an unlimited cell source for toxicity testing in drug discovery research. However, little is known about mechanisms of compound toxicity in hiPSC-Hep. In this study, modified mRNA was used to reprogram foreskin fibroblasts into hiPSC that were differentiated into hiPSC-Hep. The hiPSC-Hep expressed characteristic hepatic proteins and exhibited cytochrome P450 (CYP) enzyme activities. Next, the hiPSC-Hep, primary cryopreserved human hepatocytes (cryo-hHep) and the hepatic cell lines HepaRG and Huh7 were treated with staurosporine and acetaminophen, and the toxic responses were compared. In addition, the expression of genes regulating and executing apoptosis was analyzed in the different cell types. Staurosporine, an inducer of apoptosis, decreased ATP levels and activated caspases 3 and 7 in all cell types, but to less extent in Huh7. Furthermore, a hierarchical clustering and a principal component analysis (PCA) of the expression of apoptosis-associated genes separated cryo-hHep from the other cell types, while an enrichment analysis of apoptotic pathways identified hiPSC-Hep as more similar to cryo-hHep than the hepatic cell lines. Finally, acetaminophen induced apoptosis in hiPSC-Hep, HepaRG and Huh7, while the compound initiated a direct necrotic response in cryo-hHep. Our results indicate that for studying compounds initiating apoptosis directly hiPSC-Hep may be a good alternative to cryo-hHep. Furthermore, for compounds with more complex mechanisms of toxicity involving metabolic activation, such as acetaminophen, our data suggest that the cause of cell death depends on a balance between factors controlling death signals and the drug-metabolizing capacity.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24912781     DOI: 10.1007/s00204-014-1265-z

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  30 in total

1.  Evaluation of CYP3A4 inhibition and hepatotoxicity using DMSO-treated human hepatoma HuH-7 cells.

Authors:  Yitong Liu; Thomas J Flynn; Menghang Xia; Paddy L Wiesenfeld; Martine S Ferguson
Journal:  Cell Biol Toxicol       Date:  2015-09-16       Impact factor: 6.691

2.  New markers for tracking endoderm induction and hepatocyte differentiation from human pluripotent stem cells.

Authors:  Audrey Holtzinger; Philip R Streeter; Farida Sarangi; Scott Hillborn; Maryam Niapour; Shinichiro Ogawa; Gordon Keller
Journal:  Development       Date:  2015-10-22       Impact factor: 6.868

Review 3.  Cell sources for in vitro human liver cell culture models.

Authors:  Katrin Zeilinger; Nora Freyer; Georg Damm; Daniel Seehofer; Fanny Knöspel
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-05

Review 4.  Stem cell-derived liver cells for drug testing and disease modeling.

Authors:  Matthew D Davidson; Brenton R Ware; Salman R Khetani
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

5.  Replicative stress and alterations in cell cycle checkpoint controls following acetaminophen hepatotoxicity restrict liver regeneration.

Authors:  Preeti Viswanathan; Yogeshwar Sharma; Priya Gupta; Sanjeev Gupta
Journal:  Cell Prolif       Date:  2018-03-05       Impact factor: 6.831

6.  Synthetic human livers for modeling metabolic diseases.

Authors:  Edgar N Tafaleng; Michelle R Malizio; Ira J Fox; Alejandro Soto-Gutierrez
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 3.287

7.  Emergence of a stage-dependent human liver disease signature with directed differentiation of alpha-1 antitrypsin-deficient iPS cells.

Authors:  Andrew A Wilson; Lei Ying; Marc Liesa; Charis-Patricia Segeritz; Jason A Mills; Steven S Shen; Jyhchang Jean; Geordie C Lonza; Derek C Liberti; Alex H Lang; Jean Nazaire; Adam C Gower; Franz-Josef Müeller; Pankaj Mehta; Adriana Ordóñez; David A Lomas; Ludovic Vallier; George J Murphy; Gustavo Mostoslavsky; Avrum Spira; Orian S Shirihai; Maria I Ramirez; Paul Gadue; Darrell N Kotton
Journal:  Stem Cell Reports       Date:  2015-04-02       Impact factor: 7.765

8.  MicroRNA-122: a novel hepatocyte-enriched in vitro marker of drug-induced cellular toxicity.

Authors:  Richard Kia; Lorna Kelly; Rowena L C Sison-Young; Fang Zhang; Chris S Pridgeon; James A Heslop; Pete Metcalfe; Neil R Kitteringham; Melissa Baxter; Sean Harrison; Neil A Hanley; Zoë D Burke; Mike P Storm; Melanie J Welham; David Tosh; Barbara Küppers-Munther; Josefina Edsbagge; Philip J Starkey Lewis; Frank Bonner; Ernie Harpur; James Sidaway; Joanne Bowes; Stephen W Fenwick; Hassan Malik; Chris E P Goldring; B Kevin Park
Journal:  Toxicol Sci       Date:  2014-12-18       Impact factor: 4.849

9.  Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes.

Authors:  Han-Jin Park; Young-Jun Choi; Ji Woo Kim; Hang-Suk Chun; Ilkyun Im; Seokjoo Yoon; Yong-Mahn Han; Chang-Woo Song; Hyemin Kim
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 10.  Two Effective Routes for Removing Lineage Restriction Roadblocks: From Somatic Cells to Hepatocytes.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  Int J Mol Sci       Date:  2015-09-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.